Kefah Mokbel Analyzes Clinical Impact of B-51 Trial in Breast Cancer
Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn about a paper published on Gland Surgery:
“Translating the findings of B-51 clinical trial is particularly imperative for TNBC and HER2-positive disease, where the clinical implications are more immediate. However, in ER+/HER2- disease, the applicability of these results is less clear, and caution should be exercised before broadly extending the conclusions to this subgroup.
Our editorial commentary reflecting on this trial is available through this link.”
Title: Reevaluating regional nodal irradiation after nodal pathologic complete response to neoadjuvant chemotherapy: toward individualized de-escalation
Authors: Janhavi Venkataraman, Kefah Mokbel
More posts featuring Kefah Mokbel on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023